Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | FLT1 | P17948 | 5/20 | 0.83 |
| ▸ | FLT4 | P35916 | 4/20 | 0.83 |
| ▸ | BMP4 | P12644 | 5/20 | 0.70 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | SRC | P12931 | 2/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.57 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.57 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.57 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.57 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.57 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.57 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.57 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.57 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.57 |
| ▸ | YES1 | P07947 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7618521 | 0.87 | KDR (0.77) | KDRFLT1FLT4BMP4PRKAB2 | |
| SCHEMBL7618989 | 0.86 | KDR (1.00) | KDRFLT1FLT4BMP4PRKAB2 | |
| SCHEMBL7616736 | 0.86 | KDR (1.00) | KDRFLT1FLT4BMP4PRKAB2 | |
| SCHEMBL7610636 | 0.85 | KDR (1.00) | KDRFLT1FLT4BMP4PRKAB1 | |
| SCHEMBL7614374 | 0.84 | KDR (1.00) | KDRFLT1FLT4BMP4 | |
| SCHEMBL2059685 | 0.82 | KDR (1.00) | KDRFLT1FLT4BMP4PRKAB1 | |
| SCHEMBL7612194 | 0.80 | KDR (0.79) | KDRFLT1FLT4BMP4 | |
| SCHEMBL7614698 | 0.79 | KDR (1.00) | KDRFLT1FLT4BMP4 | |
| SCHEMBL24425220 | 0.77 | KDR (0.71) | KDRFLT1FLT4BMP4PRKAB2 | |
| SCHEMBL7610619 | 0.77 | KDR (0.73) | KDRFLT1FLT4BMP4PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | claimed |
| US-6235741-B1 | ANTICANCER AGENTS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-05-22 | — | — | US | claimed |
| US-6380203-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; TREATMENT OF TYROSINE KINASE-DEPENDENT DISEASES/CONDITIONS SUCH AS ANGIOGENESIS, CANCER, ATHEROSCLEROSIS, DIABETIC RETINOPATHY OR AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2002-04-30 | — | — | US | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-6235741-B1 | ANTICANCER AGENTS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0984692-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-02-21 | — | — | EP | disclosed |
| EP-0984692-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054093-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | KDR 318/4885FLT1 118/4885FLT4 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.